ABSTRACT

Pharmacovigilance is the medical pharmacology engaged in the identification, interpretation and mitigation of adverse effects, in particular long-term and short-term adverse reactions to medicinal products. Countries worldwide are focusing on establishment of comprehensive systems for pharmacovigilance. There are currently no approved COVID-19 therapies based on broad clinical trials evidence and therefore infection prevention, control measures and supportive care are involved in its management. While most developing countries have wellorganized pharmacovigilance systems in place, there is still a lack of basic infrastructure in developing countries to implement them. As a major center of clinical research, the Indian pharmacovigilance framework is of considerable importance for healthcare and pharmaceutical sectors. This study is an attempt to emphasis on different pharmacovigilance facets including its need, present status and ensuing prospects in India. Keywords: Adverse Drug Reactions, Clinical Trial, COVID-19, Pharmacovigilance
Publication date: 01/07/21

https://ijbpas.com/pdf/2021/July/MS_IJBPAS_2021_5535.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.7.5535